Bruker (NASDAQ:BRKR) Announces Earnings Results

Bruker (NASDAQ:BRKR) released its earnings results on Monday. The medical research company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12, Zacks reports. The firm had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business’s revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 EPS. Bruker updated its FY 2025 guidance to 1.850-1.90 EPS.

Bruker Stock Performance

NASDAQ:BRKR opened at $38.94 on Monday. Bruker has a 12-month low of $28.53 and a 12-month high of $64.64. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $5.91 billion, a PE ratio of 74.89, a price-to-earnings-growth ratio of 5.31 and a beta of 1.20. The firm has a 50-day moving average price of $34.44 and a 200 day moving average price of $36.97.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd were given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, September 23rd. Bruker’s dividend payout ratio is 38.46%.

Insider Transactions at Bruker

In related news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares of the company’s stock, valued at $581,016. This represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 27.30% of the stock is owned by company insiders.

Institutional Trading of Bruker

Large investors have recently added to or reduced their stakes in the company. Sivia Capital Partners LLC bought a new stake in Bruker during the second quarter worth about $297,000. Quantinno Capital Management LP grew its stake in Bruker by 36.7% during the second quarter. Quantinno Capital Management LP now owns 27,533 shares of the medical research company’s stock worth $1,134,000 after buying an additional 7,394 shares during the last quarter. FORA Capital LLC grew its stake in Bruker by 94.1% during the second quarter. FORA Capital LLC now owns 21,239 shares of the medical research company’s stock worth $875,000 after buying an additional 10,294 shares during the last quarter. Tidal Investments LLC grew its stake in Bruker by 116.2% during the second quarter. Tidal Investments LLC now owns 17,612 shares of the medical research company’s stock worth $726,000 after buying an additional 9,464 shares during the last quarter. Finally, Focus Partners Wealth grew its stake in Bruker by 115.0% during the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after buying an additional 6,008 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BRKR has been the subject of a number of research analyst reports. Citigroup cut their price objective on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research report on Monday, August 4th. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the company a “hold” rating in a research report on Tuesday, August 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Wednesday, October 8th. Wells Fargo & Company cut their price objective on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Tuesday, August 5th. Finally, Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the company a “buy” rating in a research report on Monday, August 4th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $51.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.